lorlatinib

cytochrome P450 family 3 subfamily A member 4 ; Homo sapiens







7 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33937953 The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants. 2021 Oct 4
2 34021354 Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity. 2021 Aug 3 2
3 31728714 The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. 2020 Feb 3
4 31863284 The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants. 2020 Feb 3
5 32399810 Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners. 2020 Jun 2
6 30660696 Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. 2019 Mar 4
7 29744867 P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. 2018 Oct 15 2